diabetes header graphic


Diabetes Mellitus Causes, Symptoms And Treatment
By Juliet Cohen
Diabetes mellitus is a metabolic disorder characterized by hyperglycemia (high blood sugar). is a disease in which the body doesn't produce or properly use insulin. Insulin is a hormone produced in the pancreas, an organ near the stomach. Insulin is needed to turn sugar and other food into energy. Three main forms of diabetes: type 1, type 2, and gestational (occurring during pregnancy),[1] which have similar signs, symptoms, and consequences, but different causes and population distributions. Ultimately, all forms are due to the beta cells of the pancreas being unable to produce sufficient insulin to prevent hyperglycemia.[2] Type 1 is usually due to autoimmune destruction of the pancreatic beta cells which produce insulin. Type 2 is characterized by tissue-wide insulin resistance and varies widely; it sometimes progresses to loss of beta cell function. Gestational is similar to type 2 diabetes, in that it involves insulin resistance; the hormones of pregnancy cause insulin resistance in those women genetically predisposed to developing this condition.

People with pre-diabetes are at increased risk for developing type 2 diabetes, heart disease and stroke. Gestational also involves a combination of inadequate insulin secretion and responsiveness, resembling type 2 in several respects. It develops during pregnancy and may improve or disappear after delivery. Insulin is called the "hunger hormone .

Causes of Mellitus

Glucose into most cells from the blood (primarily muscle and fat cells, but not

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication
<b>Condition</b>:   Type 2 Diabetes<br/><b>Interventions</b>:   Drug: Dapagliflozin;   Drug: Dapagliflozin;   Drug: Placebo<br/><b>Sponsors</b>:   Bristol-Myers Squibb;   AstraZeneca<br/><b>Not yet recruiting</b> - verified September 2010
Single-centre, Randomised, Double-blind, Placebo-controlled, Four-way Crossover Clinical Study to Investigate Safety and Tolerability and Pharmacokinetics of Single Doses of CM3.1-AC100 in Patients With Type 2 Diabetes
<b>Condition</b>:   Type II Diabetes Mellitus<br/><b>Intervention</b>:   Drug: CM3.1-AC100<br/><b>Sponsor</b>:   CellMed AG, A Subsidiary of Biocompatibles International plc.<br/><b>Recruiting</b> - verified September 2010
Euglycemic Clamp Dose-response Study Comparing Insulin Glargine U300 With Lantus® U100
<b>Condition</b>:   Type 1 Diabetes Mellitus<br/><b>Interventions</b>:   Drug: Insulin glargine (HOE901);   Drug: Insulin glargine (HOE901)<br/><b>Sponsor</b>:   Sanofi-Aventis<br/><b>Recruiting</b> - verified September 2010
Efficacy of Adding Sitagliptin or Pioglitazone to T2DM Insufficiently Controlled With Metformin and Sulfonylurea
<b>Condition</b>:   Type 2 Diabetes<br/><b>Interventions</b>:   Drug: Sitagliptin;   Drug: pioglitazone<br/><b>Sponsor</b>:   Mackay Memorial Hospital<br/><b>Recruiting</b> - verified September 2010
Benefit/Risk Evaluation of Insuman Implantable Versus Insuplant Using Medtronic MiniMed Implantable Pump System in Patients With Type 1 Diabetes
<b>Condition</b>:   Diabetes Mellitus, Type 1<br/><b>Interventions</b>:   Drug: HUMAN INSULIN (BIOSYNTHETIC);   Drug: Insuplant<br/><b>Sponsor</b>:   Sanofi-Aventis<br/><b>Not yet recruiting</b> - verified September 2010
Efficacy and Safety of Linagliptin (BI 1356) in Black/African Americans With Type 2 Diabetes With a MTT Sub-study
<b>Condition</b>:   Diabetes Mellitus, Type 2<br/><b>Interventions</b>:   Drug: Placebo;   Drug: Linagliptin<br/><b>Sponsor</b>:   Boehringer Ingelheim Pharmaceuticals<br/><b>Not yet recruiting</b> - verified September 2010
Effect of Formoterol on the Counterregulatory Hormonal Response to Hypoglycemia
<b>Condition</b>:   Type 1 Diabetes<br/><b>Intervention</b>:   Drug: Formoterol<br/><b>Sponsors</b>:   Yale University;   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)<br/><b>Recruiting</b> - verified September 2010
An Open-randomized, Balanced, Crossover Bioequivalence Study to Compare One MR Tablet of 60 mg Gliclazide and Two MR Tablets of 30 mg Gliclazide in Healthy Subjects
<b>Conditions</b>:   Hyperglycemia;   Diabetes<br/><b>Intervention</b>:   <br/><b>Sponsor</b>:   Taipei Medical University WanFang Hospital<br/><b>Recruiting</b> - verified September 2010
Insulin Administration Plus a Telemedicine System (Diabetes Interactive Diary - DID) vs Insulin Plus Common Practice
<b>Condition</b>:   Type 1 Diabetes<br/><b>Intervention</b>:   Device: Diabetes Interactive Diary (DID)<br/><b>Sponsors</b>:   Consorzio Mario Negri Sud;   Sanofi-Aventis;   LifeScan<br/><b>Recruiting</b> - verified September 2010
Safety/Efficacy Study of Subcutaneously Injected Prandial Insulins Compared to Insulin Lispro Alone in Patients With Type 1 Diabetes Mellitus
<b>Condition</b>:   Diabetes Mellitus, Type 1<br/><b>Intervention</b>:   Drug: Insulin LISPRO<br/><b>Sponsor</b>:   Halozyme Therapeutics<br/><b>Recruiting</b> - verified September 2010
Safety/Efficacy Study of Subcutaneously Injected Prandial Insulins Compared to Insulin Lispro Alone in Patients With Type 2 Diabetes Mellitus
<b>Condition</b>:   Diabetes Mellitus, Type II<br/><b>Intervention</b>:   Drug: Insulin LISPRO<br/><b>Sponsor</b>:   Halozyme Therapeutics<br/><b>Recruiting</b> - verified September 2010
Anterior and Posterior Segment Vascular Changes Following Laser and Anti-Vascular Endothelial Growth Factor (VEGF) Treatment of Diabetic Retinopathy
<b>Condition</b>:   Diabetic Macular Edema<br/><b>Intervention</b>:   <br/><b>Sponsors</b>:   University of Toronto;   Juvenile Diabetes Research Foundation<br/><b>Recruiting</b> - verified September 2010
Comparison of NN1250 Versus Insulin Glargine in Subjects With Type 2 Diabetes: An Extension Trial to NN1250-3579
<b>Condition</b>:   Diabetes Mellitus, Type 2<br/><b>Interventions</b>:   Drug: NN1250;   Drug: insulin glargine<br/><b>Sponsor</b>:   Novo Nordisk<br/><b>Not yet recruiting</b> - verified August 2010
Comparison of NN1250 With Insulin Glargine Plus Insulin Aspart With or Without Metformin and With/Without Pioglitazone in Type 2 Diabetes: An Extension Trial to NN1250-3582
<b>Condition</b>:   Diabetes Mellitus, Type 2<br/><b>Interventions</b>:   Drug: NN1250;   Drug: insulin glargine;   Drug: insulin aspart<br/><b>Sponsor</b>:   Novo Nordisk<br/><b>Recruiting</b> - verified September 2010
BI 10773 Dose Finder Study in Japanese Patients With Type 2 Diabetes Mellitus
<b>Condition</b>:   Diabetes Mellitus, Type 2<br/><b>Interventions</b>:   Drug: BI 10773;   Drug: BI 10773;   Drug: BI 10773;   Drug: BI 10773;   Drug: Placebo<br/><b>Sponsor</b>:   Boehringer Ingelheim Pharmaceuticals<br/><b>Not yet recruiting</b> - verified August 2010
Risk Factors for Low Lymphocyte Count in Patients With Type 2 Diabetes
<b>Condition</b>:   Diabetes Mellitus, Type 2<br/><b>Intervention</b>:   <br/><b>Sponsors</b>:   Bristol-Myers Squibb;   AstraZeneca<br/><b>Active, not recruiting</b> - verified August 2010
A Study of OPC-262 in Patients With Type 2 Diabetes
<b>Condition</b>:   Diabetes, Type 2<br/><b>Intervention</b>:   Drug: OPC-262<br/><b>Sponsor</b>:   Otsuka Pharmaceutical Co., Ltd.<br/><b>Recruiting</b> - verified August 2010
Clinical Trial Evaluating the Efficacy and Safety of Technosphere Insulin Inhalation Power Using the Gen2 Inhaler
<b>Condition</b>:   Type 2 Diabetes<br/><b>Interventions</b>:   Drug: Technosphere Insulin;   Drug: Insulin Aspart;   Drug: Glargine<br/><b>Sponsor</b>:   Mannkind Corporation<br/><b>Not yet recruiting</b> - verified September 2010
Glycemic Holter Study (Continuous Glucose Monitoring) -
<b>Condition</b>:   Type 2 Diabetes Mellitus<br/><b>Interventions</b>:   Drug: Vildagliptin;   Drug: Sitagliptin<br/><b>Sponsor</b>:   Novartis<br/><b>Recruiting</b> - verified August 2010
Malignancy Meta Analysis for BRL49653
<b>Condition</b>:   Diabetes Mellitus, Type 2<br/><b>Intervention</b>:   Drug: allocation of treatment with metformin or rosiglitazone<br/><b>Sponsor</b>:   GlaxoSmithKline<br/><b>Completed</b> - verified September 2010
Psychosocial Interventions in the Treatment of Youth With Type 1 Diabetes Mellitus
<b>Condition</b>:   Diabetes Mellitus<br/><b>Intervention</b>:   Behavioral: psychosocial intervention<br/><b>Sponsor</b>:   Assaf-Harofeh Medical Center<br/><b>Recruiting</b> - verified August 2010
Efficacy and Safety of Combination Therapy of Vildagliptin/Metformin in Patients in Type 2 Diabetes Mellitus (T2DM)
<b>Condition</b>:   Type 2 Diabetes Mellitus<br/><b>Intervention</b>:   Drug: vildagliptin/metformin<br/><b>Sponsor</b>:   Novartis<br/><b>Recruiting</b> - verified September 2010
Bioequivalence Study of the Fixed Dose Combination of 5 mg Saxagliptin and 500 mg Metformin XR Tablet (Manufactured in Mt Vernon, IN) Relative to 5 mg Saxagliptin Tablet and 500 mg Metformin XR Tablet (Manufactured in Evansville, IN)
<b>Condition</b>:   Diabetes Mellitus<br/><b>Interventions</b>:   Drug: saxagliptin;   Drug: metformin XR;   Drug: saxagliptin + metformin XR (FDC tablet)<br/><b>Sponsor</b>:   Bristol-Myers Squibb<br/><b>Completed</b> - verified August 2010
Bioequivalence Study of the Fixed Dose Combination of 5 mg Saxagliptin/1000 mg Metformin XR (Manufactured in Mt Vernon, IN) Relative to 5 mg of Onglyza and 2 × 500 mg Glucophage XR
<b>Condition</b>:   Diabetes Mellitus<br/><b>Interventions</b>:   Drug: saxagliptin;   Drug: Glucophage XR;   Drug: saxagliptin + metformin XR (FDC tablet)<br/><b>Sponsor</b>:   Bristol-Myers Squibb<br/><b>Completed</b> - verified August 2010
A Study in Patients With Type 2 Diabetes Mellitus (AWARD-4)
<b>Condition</b>:   Diabetes Mellitus, Type 2<br/><b>Interventions</b>:   Drug: Insulin Glargine;   Drug: LY2189266<br/><b>Sponsor</b>:   Eli Lilly and Company<br/><b>Not yet recruiting</b> - verified August 2010
Comparison of NN1250 Plus Insulin Aspart With Insulin Detemir Plus Insulin Aspart in Type 1 Diabetes: An Extension Trial to NN1250-3585
<b>Condition</b>:   Diabetes Mellitus, Type 1<br/><b>Interventions</b>:   Drug: NN1250;   Drug: insulin detemir (Levemir®);   Drug: insulin aspart<br/><b>Sponsor</b>:   Novo Nordisk<br/><b>Recruiting</b> - verified September 2010
Exploratory Study to Evaluate the Efficacy of Androxal in Controlling Blood Glucose in Men With Type-2 Diabetes Mellitus and Secondary Hypogonadism or Adult-Onset Idiopathic Hypogonadotropic Hypogonadism
<b>Conditions</b>:   Type 2 Diabetes Mellitus;   Secondary Hypogonadism<br/><b>Interventions</b>:   Drug: Placebo;   Drug: enclomiphene citrate<br/><b>Sponsor</b>:   Repros Therapeutics Inc.<br/><b>Not yet recruiting</b> - verified September 2010
Dietary Intervention With Shop Model - SHOPUS
<b>Condition</b>:   Obesity<br/><b>Intervention</b>:   Behavioral: Dietary intervention<br/><b>Sponsor</b>:   University of Copenhagen<br/><b>Recruiting</b> - verified July 2010
Adipose Tissue Gene Expression Profiles in Women With Polycystic Ovary Syndrome (PCOS) Versus Controls
<b>Condition</b>:   Polycystic Ovary Syndrome<br/><b>Intervention</b>:   <br/><b>Sponsors</b>:   The Adelaide and Meath Hospital;   University College Dublin<br/><b>Completed</b> - verified July 2008
Cardiovascular Risk Markers in Polycystic Ovary Syndrome (PCOS)
<b>Condition</b>:   Polycystic Ovary Syndrome<br/><b>Intervention</b>:   <br/><b>Sponsors</b>:   The Adelaide and Meath Hospital;   University College Dublin<br/><b>Completed</b> - verified July 2008
A 12-week, Multicentric Study to Evaluate the Safety and Efficacy of Bisoprolol in Diabetic and Hypertensive Filipinos
<b>Condition</b>:   Hypertension<br/><b>Intervention</b>:   Drug: Bisoprolole<br/><b>Sponsor</b>:   Merck KGaA<br/><b>Recruiting</b> - verified August 2010
Safety and Efficacy of Chlorthalidone + Amiloride to Elderly Patients Treatment With Arterial Hypertension
<b>Condition</b>:   Arterial Hypertension<br/><b>Interventions</b>:   Drug: Chlorthalidone 25 mg + amiloride hydrochloride 5 mg;   Drug: Higroton® Laboratório Novartis<br/><b>Sponsor</b>:   Eurofarma Laboratorios Ltda<br/><b>Not yet recruiting</b> - verified August 2010
Follow-up to Adult Height of a Cohort of Subjects Born Small for the Gestational Age and Treated With Growth Hormone
<b>Condition</b>:   Infant, Small for Gestational Age<br/><b>Intervention</b>:   <br/><b>Sponsor</b>:   Merck KGaA<br/><b>Enrolling by invitation</b> - verified September 2010


central nervous system cells), deficiency of insulin or the insensitivity of its receptors plays a central href='http://www.amazon.com/Neal-Barnards-Program-Reversing-Diabetes/dp/1594865280/ref=pd_bbs_8?ie=UTF8&s=books&qid=1214818471&/mcstylessoftware' target =_blank onMouseOver=\"uarxtip(this,event,'','Dr. Neal Barnards Program for Reversing Diabetes: The Scientifically Proven System for Reversing Diabetes Without Drugs ')\" onMouseOut=\"hideuarxtip()\"> diabetes"); keeps blood sugar levels tightly controlled, complications are less likely to develop. People with should always carry or wear a medical identification bracelet or tag to alert health care professionals to the presence of diabetes. People with type 1 who are able to maintain a healthy weight may be able to avoid the need for large doses of insulin. People with also tend to have high levels of cholesterol in the blood, so limiting the amount of saturated fat in the diet is important. Drugs may also be needed to help control the level of cholesterol in the blood. Diet management is very important in people with both types of diabetes. Doctors recommend a healthy, balanced diet and efforts to maintain a healthy weight. Some people benefit from meeting with a dietitian to develop an optimal eating plan. Diabetic ketoacidosis is also a medical emergency, because it can cause coma and death. Oral medications are available to lower blood glucose in Type II diabetics include tolbutamide, tolazamide, acetohexamide, and chlorpropamide.

Juliet Cohen writes articles for health disorders. She also writes articles for acne treatment and health tips.




Here are some more diabetes articles...

Do You Want To Die From Diabetes?
By Glenn
Diabetes mellitus is a group of diseases sharing the common characteristic of high blood sugar levels. Diabetes happens when the pancreas cannot produce Read more...
Lap Band Surgery- A Lessing For The Obese Person
By sarah wilson
Now, the obese people can have a sigh of relief because lap band surgery or gastric band surgery is there to solve their problem of excess fat. These days, obesity is a very common problem suffered Read more...